急性冠症候群市場：タイプ、製品、エンドユーザー別-2025-2030年の世界予測

急性冠症候群市場は、2023年に18億2,000万米ドルと評価され、2024年には19億4,000万米ドルに達すると予測され、CAGR 6.76％で成長し、2030年には28億9,000万米ドルに達すると予測されています。

急性冠症候群（ACS）は、突然の心臓への血流低下を伴う様々な病態を包含し、典型的には胸痛や不快感を特徴とします。ACSには心筋梗塞や不安定狭心症などが含まれ、その重大な性質と有病率の増加により、正確な市場分析が求められています。ACSの早期診断と治療の必要性は、罹患率と死亡率を低下させるために不可欠であり、高度な診断ツールと治療介入の適用が強調されています。最終用途の範囲には主に、ACSと効果的に闘うための新技術で武装した病院、外来医療センター、診断研究所が含まれます。同市場は、高齢者人口の増加、生活習慣に関連した危険因子の発生率の増加、バイオマーカーに基づく検査やポイントオブケア検査などの医療技術の進歩の影響を強く受けています。個別化医療の発展、予測分析のための人工知能の統合、ステント技術や薬物療法における技術革新に機会があります。成長の障壁としては、治療費の高騰、厳しい規制の枠組み、発展途上地域でのアクセス制限などが挙げられます。こうした機会を生かすために、企業は戦略的パートナーシップ、リスク評価のための遺伝子プロファイリングの調査、新興国市場に合わせた費用対効果の高いソリューションの開拓に注力することができます。イノベーションは、非侵襲的診断法、ウェアラブル・モニタリング・デバイス、ドラッグ・デリバリー・システムの改良といった分野で花開く可能性があります。市場競争は激しいが、優れた患者の転帰とヘルスケア提供の効率化を常に追求し、破壊の機は熟しています。企業はまた、患者の全体的な体験と長期的な健康利益を重視する、価値ベースのケアモデルへのシフトに適応しなければならないです。テクノロジーを活用し、患者中心のイノベーションに注力することで、利害関係者は課題を克服し、ACS分野の市場成長を効果的に推進することができます。

市場力学：急速に進化する急性冠症候群市場の主要市場インサイトを公開

急性冠症候群市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の心血管疾患の有病率の増加
  • 疾患の早期診断と治療への傾斜
  • 創薬および医薬品開発プロセスの増加
• 市場抑制要因
  • 急性冠症候群の治療費の高騰
• 市場機会
  • 急性冠症候群治療の進歩
  • 急性冠症候群の診断機器および治療法の改良のための継続的な研究開発
• 市場の課題
  • 急性冠症候群治療薬および治療機器の承認に対する厳しい規制要件

ポーターのファイブフォース：急性冠症候群市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：急性冠症候群市場における外部からの影響の把握

外部マクロ環境要因は、急性冠症候群市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析急性冠症候群市場における競合情勢の把握

急性冠症候群市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス急性冠症候群市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、急性冠症候群市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨急性冠症候群市場における成功への道筋を描く

急性冠症候群市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で心血管疾患の罹患率が増加
    • 病気の早期診断と治療への傾向
    • 医薬品の発見と開発プロセスの向上
  • 抑制要因
    • 急性冠症候群の治療費の高騰
  • 機会
    • 急性冠症候群の治療の進歩
    • 急性冠症候群の診断装置と治療の改良に向けた研究開発を継続中
  • 課題
    • 急性冠症候群の治療薬と機器の承認に関する厳格な規制要件
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 急性冠症候群市場：タイプ別

• 非セント上昇型心筋梗塞（NSTEMI）
• ST上昇型心筋梗塞（STEMI）
• 不安定狭心症

第7章 急性冠症候群市場：提供別

• 血液検査
• イメージング
• ストレステスト

第8章 急性冠症候群市場：エンドユーザー別

• 学術機関
• 診断センター
• 病院・クリニック

第9章 南北アメリカの急性冠症候群市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の急性冠症候群市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの急性冠症候群市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Amgen Inc.
• AstraZeneca PLC
• Baxter International, Inc.
• Bayer AG
• bioMerieux SA
• Boehringer Ingelheim International GmbH
• Boston Scientific Corporation
• DAIICHI SANKYO COMPANY, LIMITED
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• Johnson & Johnson Service, Inc.
• Koninklijke Philips N.V.
• Medtronic PLC
• Merck & Co, Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi S.A.
• Siemens AG
• Terumo Corporation
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. ACUTE CORONARY SYNDROME MARKET RESEARCH PROCESS
• FIGURE 2. ACUTE CORONARY SYNDROME MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ACUTE CORONARY SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ACUTE CORONARY SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ACUTE CORONARY SYNDROME MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ACUTE CORONARY SYNDROME MARKET DYNAMICS
• TABLE 7. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY NON-ST-ELEVATION MYOCARDIAL INFARCTION (NSTEMI), BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY ST-ELEVATION MYOCARDIAL INFARCTION (STEMI), BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY STRESS TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 29. CANADA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 31. CANADA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. CHINA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 48. CHINA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. INDIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 51. INDIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. ITALY ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 103. ITALY ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. POLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 115. POLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. QATAR ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 118. QATAR ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. ACUTE CORONARY SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. ACUTE CORONARY SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

The Acute Coronary Syndrome Market was valued at USD 1.82 billion in 2023, expected to reach USD 1.94 billion in 2024, and is projected to grow at a CAGR of 6.76%, to USD 2.89 billion by 2030.

Acute Coronary Syndrome (ACS) encompasses a spectrum of conditions associated with sudden, reduced blood flow to the heart, typically characterized by chest pain or discomfort. It includes conditions such as myocardial infarction and unstable angina, demanding precise market analysis due to its critical nature and increasing prevalence. The necessity of early diagnosis and treatment of ACS is vital to reduce morbidity and mortality rates, highlighting the application of advanced diagnostic tools and therapeutic interventions. The end-use scope primarily involves hospitals, ambulatory care centers, and diagnostic laboratories armed with emerging technologies to combat ACS effectively. The market is strongly influenced by the growing geriatric population, increasing incidence of lifestyle-related risk factors, and advancements in medical technology such as biomarker-based tests and point-of-care testing. Opportunities lie in the development of personalized medicine, integration of artificial intelligence for predictive analytics, and innovations in stent technology and pharmacotherapy. Barriers to growth include high costs of treatment, stringent regulatory frameworks, and limited accessibility in developing regions. To capitalize on these opportunities, companies can focus on strategic partnerships, research in genetic profiling for risk assessment, and the development of cost-effective solutions tailored to emerging markets. Innovation can flourish in areas like non-invasive diagnostic methods, wearable monitoring devices, and improved drug delivery systems. The market nature is highly competitive yet ripe for disruption with a constant push towards superior patient outcomes and efficiency in healthcare delivery. Companies must also adapt to the shift towards value-based care models, emphasizing overall patient experiences and long-term health benefits. By leveraging technology and focusing on patient-centric innovation, stakeholders can navigate the challenges and propel market growth in the ACS sector effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Coronary Syndrome Market

The Acute Coronary Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of cardiovascular diseases worldwide
  • Inclination toward early diagnosis and treatment of diseases
  • Rise in drug discovery and drug development process
• Market Restraints
  • High cost of treatment of acute-coronary-syndrome
• Market Opportunities
  • Advancements in the treatment of acute-coronary-syndrome
  • Ongoing R&D for development of enhanced diagnostic devices and treatment for acute-coronary-syndrome
• Market Challenges
  • Stringent regulatory requirement for approval of drugs and devices for acute-coronary-syndrome treatment

Porter's Five Forces: A Strategic Tool for Navigating the Acute Coronary Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Coronary Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Coronary Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Coronary Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Coronary Syndrome Market

A detailed market share analysis in the Acute Coronary Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Coronary Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Coronary Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Coronary Syndrome Market

A strategic analysis of the Acute Coronary Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Coronary Syndrome Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Baxter International, Inc., Bayer AG, bioMerieux SA, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Johnson & Johnson Service, Inc., Koninklijke Philips N.V., Medtronic PLC, Merck & Co, Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Siemens AG, Terumo Corporation, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Acute Coronary Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Non-St-Elevation Myocardial Infarction (NSTEMI), St-Elevation Myocardial Infarction (STEMI), and Unstable Angina.
• Based on Offering, market is studied across Blood Tests, Imaging, and Stress Test.
• Based on End User, market is studied across Academic Institutes, Diagnostic Centers, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cardiovascular diseases worldwide
    • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
    • 5.1.1.3. Rise in drug discovery and drug development process
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of treatment of acute-coronary-syndrome
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in the treatment of acute-coronary-syndrome
    • 5.1.3.2. Ongoing R&D for development of enhanced diagnostic devices and treatment for acute-coronary-syndrome
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory requirement for approval of drugs and devices for acute-coronary-syndrome treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Acute Coronary Syndrome Market, by Type

• 6.1. Introduction
• 6.2. Non-St-Elevation Myocardial Infarction (NSTEMI)
• 6.3. St-Elevation Myocardial Infarction (STEMI)
• 6.4. Unstable Angina

7. Acute Coronary Syndrome Market, by Offering

• 7.1. Introduction
• 7.2. Blood Tests
• 7.3. Imaging
• 7.4. Stress Test

8. Acute Coronary Syndrome Market, by End User

• 8.1. Introduction
• 8.2. Academic Institutes
• 8.3. Diagnostic Centers
• 8.4. Hospitals & Clinics

9. Americas Acute Coronary Syndrome Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Acute Coronary Syndrome Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Acute Coronary Syndrome Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Amgen Inc.
• 3. AstraZeneca PLC
• 4. Baxter International, Inc.
• 5. Bayer AG
• 6. bioMerieux SA
• 7. Boehringer Ingelheim International GmbH
• 8. Boston Scientific Corporation
• 9. DAIICHI SANKYO COMPANY, LIMITED
• 10. Dr. Reddy's Laboratories Ltd.
• 11. Eli Lilly and Company
• 12. F. Hoffmann-La Roche Ltd.
• 13. Gilead Sciences, Inc.
• 14. Johnson & Johnson Service, Inc.
• 15. Koninklijke Philips N.V.
• 16. Medtronic PLC
• 17. Merck & Co, Inc.
• 18. Novartis AG
• 19. Pfizer Inc.
• 20. Regeneron Pharmaceuticals Inc.
• 21. Sanofi S.A.
• 22. Siemens AG
• 23. Terumo Corporation
• 24. Teva Pharmaceutical Industries Ltd.